Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer

PURPOSE: Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (EGFR) mutation testing (e.g., for T790M mutations), and the subsequent administration of third-generation EGFR-tyrosine kinase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Min Hee, Kim, Hye Ryun, Ahn, Beung-Chul, Heo, Su Jin, Kim, Jee Hung, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536394/
https://www.ncbi.nlm.nih.gov/pubmed/31124335
http://dx.doi.org/10.3349/ymj.2019.60.6.525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536394/
https://www.ncbi.nlm.nih.gov/pubmed/31124335
http://dx.doi.org/10.3349/ymj.2019.60.6.525

Ejemplares similares